BSX's recent earnings showcase robust revenue growth, aligning with its projected trajectory. Technical indicators such as the 50‑day MA still lie below the price, supporting the existing bullish bias.

Sector-wide momentum continues to favor medical device leaders, keeping market sentiment for BSX positive. The absence of sector‑wide headwinds suggests investors will likely maintain support.

Long‑term fundamentals remain favorable, with a low recall frequency and diversified product pipeline mitigating risks. Macroeconomic exposure stays modest, so a bearish shift would require extreme conditions.

RSI sits at 58, confirming bullish momentum, while the 20‑day EMA crosses above the 50‑day EMA, a classic bullish signal. Volume has risen consistently, reinforcing the uptrend.